TY - JOUR
AU - Muhs, A.
AU - Hickmann, D.T.
AU - Pihlgren, M.
AU - Chuard, N.
AU - Giriens, V.
AU - Meerschman, C.
AU - van der Auwera, I.
AU - van Leuven, F.
AU - Sugawara, M.
AU - Weingertner, M.C.
AU - Bechinger, B.
AU - Greferath, R.
AU - Kolonko, N.
AU - Nagel-Steger, L.
AU - Riesner, D.
AU - Brady, R.O.
AU - Pfeifer, A.
AU - Nicolau, C.
TI - Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
JO - Proceedings of the National Academy of Sciences of the United States of America
VL - 104
SN - 0027-8424
CY - Washington, DC
PB - Academy
M1 - PreJuSER-60181
SP - 9810 - 9815
PY - 2007
N1 - Record converted from VDB: 12.11.2012
AB - We investigated the therapeutic effects of two different versions of Abeta(1-15 (16)) liposome-based vaccines. Inoculation of APP-V717IxPS-1 (APPxPS-1) double-transgenic mice with tetra-palmitoylated amyloid 1-15 peptide (palmAbeta(1-15)), or with amyloid 1-16 peptide (PEG-Abeta(1-16)) linked to a polyethyleneglycol spacer at each end, and embedded within a liposome membrane, elicited fast immune responses with identical binding epitopes. PalmAbeta(1-15) liposomal vaccine elicited an immune response that restored the memory defect of the mice, whereas that of PEG-Abeta(1-16) had no such effect. Immunoglobulins that were generated were predominantly of the IgG class with palmAbeta(1-15), whereas those elicited by PEG-Abeta(1-16) were primarily of the IgM class. The IgG subclasses of the antibodies generated by both vaccines were mostly IgG2b indicating noninflammatory Th2 isotype. CD and NMR revealed predominantly beta-sheet conformation of palmAbeta(1-15) and random coil of PEG-Abeta(1-16). We conclude that the association with liposomes induced a variation of the immunogenic structures and thereby different immunogenicities. This finding supports the hypothesis that Alzheimer's disease is a "conformational" disease, implying that antibodies against amyloid sequences in the beta-sheet conformation are preferred as potential therapeutic agents.
KW - Alzheimer Disease: prevention & control
KW - Alzheimer Vaccines: immunology
KW - Alzheimer Vaccines: pharmacology
KW - Amyloid beta-Peptides: immunology
KW - Amyloid beta-Peptides: metabolism
KW - Amyloid beta-Protein Precursor: genetics
KW - Analysis of Variance
KW - Animals
KW - Antigens: immunology
KW - Brain: immunology
KW - Brain: metabolism
KW - Cytokines: metabolism
KW - Enzyme-Linked Immunosorbent Assay
KW - Epitope Mapping
KW - Liposomes: immunology
KW - Mice
KW - Mice, Transgenic
KW - Nuclear Magnetic Resonance, Biomolecular
KW - Oligopeptides: genetics
KW - Peptide Fragments: immunology
KW - Recognition (Psychology): drug effects
KW - Alzheimer Vaccines (NLM Chemicals)
KW - Amyloid beta-Peptides (NLM Chemicals)
KW - Amyloid beta-Protein Precursor (NLM Chemicals)
KW - Antigens (NLM Chemicals)
KW - Cytokines (NLM Chemicals)
KW - Liposomes (NLM Chemicals)
KW - Oligopeptides (NLM Chemicals)
KW - PS1 antigen (NLM Chemicals)
KW - Peptide Fragments (NLM Chemicals)
KW - J (WoSType)
LB - PUB:(DE-HGF)16
C6 - pmid:17517595
C2 - pmc:PMC1887581
UR - <Go to ISI:>//WOS:000247114100049
DO - DOI:10.1073/pnas.0703137104
UR - https://juser.fz-juelich.de/record/60181
ER -